Browse > Article
http://dx.doi.org/10.14348/molcells.2017.0096

Molecular and Cellular Basis of Neurodegeneration in Alzheimer's Disease  

Jeong, Sangyun (Department of Molecular Biology, Chonbuk National University)
Publication Information
Molecules and Cells / v.40, no.9, 2017 , pp. 613-620 More about this Journal
Abstract
The most common form of senile dementia is Alzheimer's disease (AD), which is characterized by the extracellular deposition of amyloid ${\beta}-peptide$ ($A{\beta}$) plaques and the intracellular formation of neurofibrillary tangles (NFTs) in the cerebral cortex. Tau abnormalities are commonly observed in many neurodegenerative diseases including AD, Parkinson's disease, and Pick's disease. Interestingly, tau-mediated formation of NFTs in AD brains shows better correlation with cognitive impairment than $A{\beta}$ plaque accumulation; pathological tau alone is sufficient to elicit frontotemporal dementia, but it does not cause AD. A growing amount of evidence suggests that soluble $A{\beta}$ oligomers in concert with hyperphosphorylated tau (pTau) serve as the major pathogenic drivers of neurodegeneration in AD. Increased $A{\beta}$ oligomers trigger neuronal dysfunction and network alternations in learning and memory circuitry prior to clinical onset of AD, leading to cognitive decline. Furthermore, accumulated damage to mitochondria in the course of aging, which is the best-known nongenetic risk factor for AD, may collaborate with soluble $A{\beta}$ and pTau to induce synapse loss and cognitive impairment in AD. In this review, I summarize and discuss the current knowledge of the molecular and cellular biology of AD and also the mechanisms that underlie $A{\beta}-mediated$ neurodegeneration.
Keywords
Alzheimer's disease; amyloid ${\beta}-peptide$; APP; neurodegeneration; tau;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Lacor, P.N., Buniel, M.C., Furlow, P.W., Clemente, A.S., Velasco, P.T., Wood, M., Viola, K.L., and Klein, W.L. (2007). $A{\beta}$ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 27, 796-807.   DOI
2 Lambert, J.C., and Amouyel, P. (2011). Genetics of Alzheimer's disease: new evidences for an old hypothesis? Curr. Opin. Genet. Dev. 21, 295-301.   DOI
3 Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., Naj, A.C., Sims, R., Bellenguez, C., DeStafano, A.L., Bis, J.C., Beecham, G.W., Grenier- Boley, B., et al. (2013). Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet. 45, 1452-1458.   DOI
4 Leissring, M.A., Murphy, M.P., Mead, T.R., Akbari, Y., Sugarman, M.C., Jannatipour, M., Anliker, B., Müller, U., Saftig, P., De Strooper, B, et al. (2002). A physiologic signaling role for the ${\gamma}$-secretasederived intracellular fragment of APP. Proc. Natl. Acad. Sci. USA 99, 4697-4702.   DOI
5 Li, S., Hong, S., Shepardson, N.E., Walsh, D.M., Shankar, G.M., and Selkoe, D. (2009). Soluble oligomers of amyloid b protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62, 788-801.   DOI
6 Lin, L., Georgievska, B., Mattsson, A., and Isacson, O. (1999). Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation. Proc. Natl. Acad. Sci. USA 96, 12108-12113.   DOI
7 Lue, L.F., Kuo, Y.M., Roher, A.E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J.H., Rydel, R.E., and Rogers, J. (1999). Soluble amyloid ${\beta}$ peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155, 853-862.   DOI
8 Luo, Y., Bolon, B., Kahn, S., Bennett, B.D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., et al. (2001). Mice deficient in BACE1, the Alzheimer's ${\beta}$-secretase, have normal phenotype and abolished ${\beta}$-amyloid generation. Nat. Neurosci. 4, 231-232.   DOI
9 Masters, C.L., Simms, G., Weinman, N.A., Multhaup, G., McDonald, B.L., and Beyreuther, K. (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA 82, 4245-4249.   DOI
10 McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M.P., Beard, J., Das, P., et al. (2005). $A{\beta}42$ is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47, 191-199.   DOI
11 McLean, C.A., Cherny, R.A., Fraser, F.W., Fuller, S.J., Smith, M.J., Beyreuther, K., Bush, A.I., and Masters, C.L. (1999). Soluble pool of $A{\beta}$ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860-866.   DOI
12 Muller, T., Meyer, H.E., Egensperger, R., and Marcus, K. (2008). The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for Alzheimer's disease. Prog. Neurobiol. 85, 393-406.   DOI
13 Muller-Schiffmann A, Herring A, Abdel-Hafiz L, Chepkova AN, Schäble S, Wedel D, Horn AH, Sticht H, de Souza Silva MA, Gottmann K, et al. (2015). Amyloid-${\beta}$ dimers in the absence of plaque pathology impair learning and synaptic plasticity. Brain 139, 509-525.
14 Nelson, P.T., Alafuzoff, I., Bigio, E.H., Bouras, C., Braak, H., Cairns, N.J., Castellani, R.J., Crain, B.J., Davies, P., Del Tredici, K., et al. (2012). Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 71, 362-381.   DOI
15 Palop, J.J., and Mucke, L. (2016). Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat. Rev. Neurosci. 17, 777-792.   DOI
16 Nhan, H.S., Chiang, K., and Koo, E.H. (2016). The multifaceted nature of amyloid precursor protein and its proteolytic fragments: friends and foes. Acta Neuropathol. 129, 1-19.
17 Nikolaev, A., McLaughlin, T., O'Leary, D.D., and Tessier-Lavigne, M. (2009). APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457, 981-989.   DOI
18 Palop, J.J., and Mucke, L. (2010). Amyloid-${\beta}$-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 13, 812-818.   DOI
19 Reddy, P.H., and Beal, M.F. (2008). Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol. Med. 14, 45-53.   DOI
20 Reddy P.H., and Reddy, T.P. (2011). Mitochondria as a therapeutic target for aging and neurodegenerative diseases. Curr. Alzheimer Res. 8, 393-409.   DOI
21 Reinhard, C., Hébert, S.S., and De Strooper, B. (2005). The amyloid-${\beta}$ precursor protein: integrating structure with biological function. EMBO J. 24, 3996-4006.   DOI
22 Ring, S., Weyer, S.W., Kilian, S.B., Waldron, E., Pietrzik, C.U., Filippov, M.A., Herms, J., Buchholz, C., Eckman, C.B., Korte, M., et al. (2007). The secreted ${\beta}$-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. J. Neurosci. 27, 7817-7826.   DOI
23 Shankar, G.M., Bloodgood, B.L., Townsend, M., Walsh, D.M., Selkoe, D.J., and Sabatini, B.L. (2007). Natural oligomers of the Alzheimer amyloid-${\beta}$ protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27, 2866-2875.   DOI
24 Roberson, E.D., Scearce-Levie, K., Palop, J.J., Yan, F., Cheng, I.H., Wu, T., Gerstein, H., Yu, G.Q., and Mucke, L. (2007). Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754.   DOI
25 Ryan, K.A., and Pimplikar, S.W. (2005). Activation of GSK-3 and phosphorylation of CRMP2 in transgenic mice expressing APP intracellular domain. J. Cell Biol. 171, 327-335.   DOI
26 Selkoe, D.J. (1998). The cell biology of ${\beta}$-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 8, 447-453.   DOI
27 Shankar, G.M., Li, S., Mehta, T.H., Garcia-Munoz, A., Shepardson, N.E., Smith, I., Brett, F.M., Farrell, M.A., Rowan, M.J., Lemere, C.A., et al. (2008). Amyloid-${\beta}$ protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842.   DOI
28 Simic, G., Kostovic, I., Winblad, B., and Bogdanovic, N. (1997). Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer's disease. J. Comp. Neurol. 379, 482-494.   DOI
29 Skovronsky, D.M., Moore, D.B., Milla, M.E., Doms, R.W., and Lee, V.M. (2000). Protein kinase C-dependent ${\alpha}$-secretase competes with ${\beta}$-secretase for cleavage of amyloid-${\beta}$ precursor protein in the trans- Golgi network. J. Biol. Chem. 275, 2568-2575.   DOI
30 Small, S.A., and Petsko, G.A. (2015). Retromer in Alzheimer disease, Parkinson disease and other neurological disorders. Nat. Rev. Neurosci. 16, 126-132.   DOI
31 Spires-Jones, T.L., and Hyman, B.T. (2014). The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron 82, 756-771.   DOI
32 Strittmatter, W.J., Saunders, A.M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G.S., and Roses, A.D. (1993). Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 1977-1981.   DOI
33 Struhl, G., and Adachi, A. (1998). Nuclear access and action of notch in vivo. Cell 93, 649-660.   DOI
34 Swerdlow, R.H., Burns, J.M., and Khan, S.M. (2010). The Alzheimer's disease mitochondrial cascade hypothesis. J. Alzheimers Dis. 20, 265-279.   DOI
35 Talantova, M., Sanz-Blasco, S., Zhang, X., Xia, P., Akhtar, M.W., Okamoto, S., Dziewczapolski, G., Nakamura, T., Cao, G., Pratt, A.E., et al. (2013). $A{\beta}$ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc. Natl. Acad. Sci. USA 110, E2518-E2527.   DOI
36 Tanzi, R.E. (2012). The genetics of Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006296.
37 Terry, R.D., Masliah, E., Salmon, D.P., Butters, N., DeTeresa, R., Hill, R., Hansen, L.A., and Katzman, R. (1991). Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572-580.   DOI
38 Tu, S., Okamoto, S., Lipton, S.A., and Xu, H. (2014). Oligomeric $A{\beta}$ induced synaptic dysfunction in Alzheimer's disease. Mol. Neurodegener. 9, 48.   DOI
39 Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J., and Selkoe, D.J. (2002). Naturally secreted oligomers of amyloid ${\beta}$ protein potently inhibit hippocampal longterm potentiation in vivo. Nature 416, 535-539.   DOI
40 Wakabayashi, T., Craessaerts, K., Bammens, L., Bentahir, M., Borgions, F., Herdewijn, P., Staes, A., Timmerman, E., Vandekerckhove, J., Rubinstein, E., et al. (2009). Analysis of the ${\gamma}$- secretase interactome and validation of its association with tetraspanin-enriched microdomains. Nat. Cell Biol. 11, 1340-1346.   DOI
41 Wang, X., Wang, Z., Chen, Y., Huang, X., Hu, Y., Zhang, R., Ho, M.S., and Xue, L. (2014). FoxO mediates APP-induced AICD-dependent cell death. Cell Death Dis. 5, e1233.   DOI
42 Wei, W., Nguyen, L.N., Kessels, H.W., Hagiwara, H., Sisodia, S., and Malinow, R. (2010). Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat. Neurosci. 13, 190-196.   DOI
43 Whitehouse, P.J., Price, D.L., Clark, A.W., Coyle, J.T., and DeLong, M.R. (1981). Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 10, 122-126.   DOI
44 Wirths, O., Breyhan, H., Cynis, H., Schilling, S., Demuth, H.U., and Bayer, T.A. (2009). Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol. 118, 487-496.   DOI
45 Bai, X.C., Yan, C., Yang, G., Lu, P., Ma, D., Sun, L., Zhou, R., Scheres, S.H., and Shi, Y. (2015). An atomic structure of human ${\gamma}$-secretase. Nature 525, 212-217.   DOI
46 Wirths, O., and Bayer, T.A. (2010). Neuron loss in transgenic mouse models of Alzheimer's disease. Int. J. Alzheimers Dis. 2010.
47 Zhang, Z., Nadeau, P., Song, W., Donoviel, D., Yuan, M., Bernstein, A., and Yankner, B.A. (2000). Presenilins are required for ${\gamma}$-secretase cleavage of ${\beta}$-APP and transmembrane cleavage of Notch-1. Nat. Cell Biol. 2, 463-465.   DOI
48 Zhou, S., Zhou, H., Walian, P.J., and Jap, B.K. (2005). CD147 is a regulatory subunit of the ${\gamma}$-secretase complex in Alzheimer's disease amyloid ${\beta}$-peptide production. Proc. Natl. Acad. Sci. USA 102, 7499-7504.   DOI
49 Zhu, C.W., Livote, E.E., Scarmeas, N., Albert, M., Brandt, J., Blacker, D., Sano, M., and Stern, Y. (2013). Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease. Alzheimers Dementia 9, 733-740.   DOI
50 Arendt, T. (2009). Synaptic degeneration in Alzheimer's disease. Acta Neuropathol. 118, 167-179.   DOI
51 Ballatore, C., Lee, V.M., and Trojanowski, J.Q. (2007). Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 8, 663-672.
52 Bartus, R.T., Dean, R.L. 3rd, Beer, B., and Lippa, A.S. (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science 217, 408-414.   DOI
53 Bateman, R.J., Aisen, P.S., De Strooper, B., Fox, N.C., Lemere, C.A., Ringman, J.M., Salloway, S., Sperling, R.A., Windisch, M., and Xiong, C. (2011). Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res. Ther. 3, 1.
54 Gunawardena, S., and Goldstein, L.S. (2001). Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron 32, 389-401.   DOI
55 Gomez-Isla, T., Price, J.L., McKeel, D.W. Jr., Morris, J.C., Growdon, J.H., and Hyman, B.T. (1996). Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Neurosci. 16, 4491-4500.   DOI
56 Grimm, M.O., Grimm, H.S., Pätzold, A.J., Zinser, E.G., Halonen, R., Duering, M., Tschape, J.A., De Strooper, B., Muller, U., Shen, J., et al. (2005). Regulation of cholesterol and sphingomyelin metabolism by amyloid-${\beta}$ and presenilin. Nat. Cell Biol. 7, 1118-1123.   DOI
57 Grundke-Iqbal, I., Iqbal, K., Tung, Y.C., Quinlan, M., Wisniewski, H.M., and Binder, L.I. (1986). Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. USA 83, 4913-4917.   DOI
58 Hamid, R., Kilger, E., Willem, M., Vassallo, N., Kostka, M., Bornhovd, C., Reichert, A.S., Kretzschmar, H.A., Haass, C., and Herms, J. (2007). Amyloid precursor protein intracellular domain modulates cellular calcium homeostasis and ATP content. J. Neurochem. 102, 1264-1275.   DOI
59 Brown, M.S., Ye, J., Rawson, R.B., and Goldstein, J.L. (2000). Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 100, 391-398.   DOI
60 Bu, G. (2009). Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10, 333-344.   DOI
61 Cai, H., Wang, Y., McCarthy, D., Wen, H., Borchelt, D.R., Price, D.L., and Wong, P.C. (2001). BACE1 is the major ${\beta}$-secretase for generation of $A{\beta}$ peptides by neurons. Nat. Neurosci. 4, 233-234.   DOI
62 Canter, R.G., Penney, J., and Tsai L.H. (2016). The road to restoring neural circuits for the treatment of Alzheimer's disease. Nature 539, 187-196.   DOI
63 Chasseigneaux, S., and Allinquant, B. (2012). Functions of $A{\beta}$, $sAPP{\alpha}$ and $sAPP{\beta}$ : similarities and differences. J. Neurochem. 120, 99-108.   DOI
64 Chen, Q.S., Kagan, B.L., Hirakura, Y., and Xie, C.W. (2000). Impairment of hippocampal long-term potentiation by Alzheimer amyloid ${\beta}$-peptides. J. Neurosci. Res. 60, 65-72.   DOI
65 Chen, F., Hasegawa, H., Schmitt-Ulms, G., Kawarai, T., Bohm, C., Katayama, T., Gu, Y., Sanjo, N., Glista, M., Rogaeva, E., et al. (2006). TMP21 is a presenilin complex component that modulates ${\gamma}$- secretase but not ${\varepsilon}$-secretase activity. Nature 440, 1208-1212.   DOI
66 Cho, D.H., Nakamura, T., Fang, J., Cieplak, P., Godzik, A., Gu, Z., and Lipton, S.A. (2009). S-nitrosylation of Drp1 mediates ${\beta}$-amyloidrelated mitochondrial fission and neuronal injury. Science 324, 102-105.   DOI
67 Herreman, A., Serneels, L., Annaert, W., Collen, D., Schoonjans, L., and De Strooper, B. (2000). Total inactivation of ${\gamma}$-secretase activity in presenilin-deficient embryonic stem cells. Nat. Cell Biol. 2, 461-462.   DOI
68 Hardy, J.A., and Higgins, G.A. (1992). Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185.   DOI
69 Hardy, J., and Selkoe, D.J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.   DOI
70 He, G., Luo, W., Li, P., Remmers, C., Netzer, W.J., Hendrick, J., Bettayeb, K., Flajolet, M., Gorelick, F., Wennogle, L.P., et al. (2010). Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 467, 95-98.   DOI
71 Hong, Y.G., Roh, S., Paik, D., and Jeong, S. (2017). Development of a reporter system for in vivo monitoring of ${\gamma}$-secretase activity in Drosophila. Mol. Cells 40, 73-81.   DOI
72 Hsieh, H., Boehm, J., Sato, C., Iwatsubo, T., Tomita, T., Sisodia, S., and Malinow, R. (2006). AMPAR removal underlies Ab-induced synaptic depression and dendritic spine loss. Neuron 52, 831-843.   DOI
73 Huang, Y., and Mucke, L. (2012). Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222.   DOI
74 Hung, A.Y., Haass, C., Nitsch, R.M., Qiu, W.Q., Citron, M., Wurtman, R.J., Growdon, J.H., and Selkoe, D.J. (1993). Activation of protein kinase C inhibits cellular production of the amyloid ${\beta}$-protein. J. Biol. Chem. 268, 22959-22962.
75 DeKosky, S.T., and Scheff, S.W. (1990). Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol. 27, 457-464.   DOI
76 Cleary, J.P., Walsh, D.M., Hofmeister, J.J., Shankar, G.M., Kuskowski, M.A., Selkoe, D.J., and Ashe, K.H. (2005). Natural oligomers of the amyloid-${\beta}$ protein specifically disrupt cognitive function. Nat. Neurosci. 8, 79-84.   DOI
77 Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, G.W., Roses, A.D., Haines, J.L., and Pericak- Vance, M.A. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.   DOI
78 Cullen, W.K., Suh, Y.H., Anwyl, R., and Rowan, M.J. (1997). Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport 8, 3213-3217.   DOI
79 De Strooper, B. (2003). Aph-1, Pen-2, and Nicastrin with Presenilin generate an active ${\gamma}$-Secretase complex. Neuron 38, 9-12.   DOI
80 De Strooper, B. (2007). Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 8, 141-146.   DOI
81 De Strooper, B., and Karran, E. (2016). The Cellular phase of Alzheimer's disease. Cell 164, 603-615.   DOI
82 Dineley, K.T., Bell, K.A., Bui, D., and Sweatt, J.D. (2002). ${\beta}$-Amyloid peptide activates ${\alpha}7$ nicotinic acetylcholine receptors expressed in Xenopus oocytes. J. Biol. Chem. 277, 25056-25061.   DOI
83 Esler, W.P., and Wolfe, M.S. (2001). A portrait of Alzheimer secretases--new features and familiar faces. Science 293, 1449-1454.   DOI
84 Kandel, E.R., Dudai, Y., and Mayford, M.R. (2014). The molecular and systems biology of memory. Cell 157, 163-186.   DOI
85 Hutton, M., Lendon, C.L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998). Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705.   DOI
86 IIhara, Y., Nukina, N., Miura, R., and Ogawara, M. (1986). Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J. Biochem. 99, 1807-1810.
87 Jarrett, J.T., Berger, E.P., and Lansbury, P.T. Jr. (1993). The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32, 4693-4697.   DOI
88 Kang, J., Lemaire, H.G., Unterbeck, A., Salbaum, J.M., Masters, C.L., Grzeschik, K.H., Multhaup, G., Beyreuther, K., and Muller-Hill, B. (1987). The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733-736.   DOI
89 Klein, A.M., Kowall, N.W., and Ferrante, R.J. (1999). Neurotoxicity and oxidative damage of beta amyloid 1-42 versus beta amyloid 1-40 in the mouse cerebral cortex. Ann. N. Y. Acad. Sci. 893, 314-320.   DOI
90 Knott, A.B., Perkins, G., Schwarzenbacher, R., and Bossy-Wetzel, E. (2008). Mitochondrial fragmentation in neurodegeneration. Nat. Rev. Neurosci. 9, 505-518.   DOI
91 Kosik, K.S., Joachim, C.L., and Selkoe, D.J. (1986). Microtubuleassociated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl. Acad. Sci. USA 83, 4044-4048.   DOI
92 Ghosal, K., Vogt, D.L., Liang, M., Shen, Y., Lamb, B.T., and Pimplikar, S.W. (2009). Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc. Natl. Acad. Sci. USA 106, 18367-18372.   DOI
93 Figueiredo, C.P., Clarke, J.R., Ledo, J.H., Ribeiro, F.C., Costa, C.V., Melo, H.M., Mota-Sales, A.P., Saraiva, L.M., Klein, W.L., Sebollela, A., et al. (2013). Memantine rescues transient cognitive impairment caused by high-molecular-weight $a{\beta}$ oligomers but not the persistent impairment induced by low-molecular-weight oligomers. J. Neurosci. 33, 9626-9634.   DOI
94 Furukawa, K., Sopher, B.L., Rydel, R.E., Begley, J.G., Pham, D.G., Martin, G.M., Fox, M., and Mattson, M.P. (1996). Increased activityregulating and neuroprotective efficacy of ${\alpha}$-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J. Neurochem. 67, 1882-1896.
95 Gendron, T.F., and Petrucelli, L. (2009). The role of tau in neurodegeneration. Mol. Neurodegener. 4, 13.   DOI
96 Giliberto, L., d'Abramo, C., Acker, C.M., Davies, P., and D'Adamio, L. (2010). Transgenic expression of the amyloid-${\beta}$ precursor proteinintracellular domain does not induce Alzheimer's Disease-like traits in vivo. PLoS One 5, e11609.   DOI
97 Goedert, M. (2015). NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled $A{\beta}$, tau, and ${\alpha}$-synuclein. Science 349, 1255555.   DOI
98 Goedert, M., and Spillantini, M.G. (2006). A century of Alzheimer's disease. Science 314, 777-781.   DOI